178 related articles for article (PubMed ID: 37649269)
1. Differential responses of disease-related GRIN variants located in pore-forming M2 domain of N-methyl-D-aspartate receptor to FDA-approved inhibitors.
Song R; Zhang J; Perszyk RE; Camp CR; Tang W; Kannan V; Li J; Xu Y; Chen J; Li Y; Liang SH; Traynelis SF; Yuan H
J Neurochem; 2023 Aug; ():. PubMed ID: 37649269
[TBL] [Abstract][Full Text] [Related]
2. De novo GRIN variants in NMDA receptor M2 channel pore-forming loop are associated with neurological diseases.
Li J; Zhang J; Tang W; Mizu RK; Kusumoto H; XiangWei W; Xu Y; Chen W; Amin JB; Hu C; Kannan V; Keller SR; Wilcox WR; Lemke JR; Myers SJ; Swanger SA; Wollmuth LP; Petrovski S; Traynelis SF; Yuan H
Hum Mutat; 2019 Dec; 40(12):2393-2413. PubMed ID: 31429998
[TBL] [Abstract][Full Text] [Related]
3. De novo GRIN variants in M3 helix associated with neurological disorders control channel gating of NMDA receptor.
Xu Y; Song R; Perszyk RE; Chen W; Kim S; Park KL; Allen JP; Nocilla KA; Zhang J; XiangWei W; Tankovic A; McDaniels ED; Sheikh R; Mizu RK; Karamchandani MM; Hu C; Kusumoto H; Pecha J; Cappuccio G; Gaitanis J; Sullivan J; Shashi V; Petrovski S; Jauss RT; Lee HK; Bozarth X; Lynch DR; Helbig I; Pierson TM; Boerkoel CF; Myers SJ; Lemke JR; Benke TA; Yuan H; Traynelis SF
Cell Mol Life Sci; 2024 Mar; 81(1):153. PubMed ID: 38538865
[TBL] [Abstract][Full Text] [Related]
4. Positive allosteric modulators that target NMDA receptors rectify loss-of-function GRIN variants associated with neurological and neuropsychiatric disorders.
Tang W; Liu D; Traynelis SF; Yuan H
Neuropharmacology; 2020 Oct; 177():108247. PubMed ID: 32712275
[TBL] [Abstract][Full Text] [Related]
5. Recurrent seizure-related GRIN1 variant: Molecular mechanism and targeted therapy.
Xu Y; Song R; Chen W; Strong K; Shrey D; Gedela S; Traynelis SF; Zhang G; Yuan H
Ann Clin Transl Neurol; 2021 Jul; 8(7):1480-1494. PubMed ID: 34227748
[TBL] [Abstract][Full Text] [Related]
6. Characterization of mice carrying a neurodevelopmental disease-associated GluN2B(L825V) variant.
Candelas Serra M; Kuchtiak V; Kubik-Zahorodna A; Kysilov B; Fili K; Hrcka Krausova B; Abramova V; Dobrovolski M; Harant K; Bozikova P; Cerny J; Prochazka J; Kasparek P; Sedlacek R; Balik A; Smejkalova T; Vyklicky L
J Neurosci; 2024 Jun; ():. PubMed ID: 38926089
[No Abstract] [Full Text] [Related]
7. Disease-Associated Variants in GRIN1, GRIN2A and GRIN2B genes: Insights into NMDA Receptor Structure, Function, and Pathophysiology.
Korinek M; Serra MC; Abdel Rahman F; Dobrovolski M; Kuchtiak V; Abramova V; Fili K; Tomovic E; Hrcka Krausova B; Krusek J; Cerny J; Vyklicky L; Balik A
Physiol Res; 2024 May; ():. PubMed ID: 38836461
[TBL] [Abstract][Full Text] [Related]
8. Disease-associated GRIN protein truncating variants trigger NMDA receptor loss-of-function.
Santos-Gómez A; Miguez-Cabello F; García-Recio A; Locubiche-Serra S; García-Díaz R; Soto-Insuga V; Guerrero-López R; Juliá-Palacios N; Ciruela F; García-Cazorla À; Soto D; Olivella M; Altafaj X
Hum Mol Genet; 2021 Feb; 29(24):3859-3871. PubMed ID: 33043365
[TBL] [Abstract][Full Text] [Related]
9. Spectrum of NMDA Receptor Variants in Neurodevelopmental Disorders and Epilepsy.
Gjerulfsen CE; Krey I; Klöckner C; Rubboli G; Lemke JR; Møller RS
Methods Mol Biol; 2024; 2799():1-11. PubMed ID: 38727899
[TBL] [Abstract][Full Text] [Related]
10. Novel neuroactive steroids as positive allosteric modulators of NMDA receptors: mechanism, site of action, and rescue pharmacology on GRIN variants associated with neurological conditions.
Tang W; Beckley JT; Zhang J; Song R; Xu Y; Kim S; Quirk MC; Robichaud AJ; Diaz ES; Myers SJ; Doherty JJ; Ackley MA; Traynelis SF; Yuan H
Cell Mol Life Sci; 2023 Jan; 80(2):42. PubMed ID: 36645496
[TBL] [Abstract][Full Text] [Related]
11. Functional effects of disease-associated variants reveal that the S1-M1 linker of the NMDA receptor critically controls channel opening.
Xie L; McDaniel MJ; Perszyk RE; Kim S; Cappuccio G; Shapiro KA; Muñoz-Cabello B; Sanchez-Lara PA; Grand K; Zhang J; Nocilla KA; Sheikh R; Armengol L; Romano R; Pierson TM; Yuan H; Myers SJ; Traynelis SF
Cell Mol Life Sci; 2023 Mar; 80(4):110. PubMed ID: 37000222
[TBL] [Abstract][Full Text] [Related]
12. Molecular Mechanism of Disease-Associated Mutations in the Pre-M1 Helix of NMDA Receptors and Potential Rescue Pharmacology.
Ogden KK; Chen W; Swanger SA; McDaniel MJ; Fan LZ; Hu C; Tankovic A; Kusumoto H; Kosobucki GJ; Schulien AJ; Su Z; Pecha J; Bhattacharya S; Petrovski S; Cohen AE; Aizenman E; Traynelis SF; Yuan H
PLoS Genet; 2017 Jan; 13(1):e1006536. PubMed ID: 28095420
[TBL] [Abstract][Full Text] [Related]
13. Indistinguishable synaptic pharmacodynamics of the N-methyl-D-aspartate receptor channel blockers memantine and ketamine.
Emnett CM; Eisenman LN; Taylor AM; Izumi Y; Zorumski CF; Mennerick S
Mol Pharmacol; 2013 Dec; 84(6):935-47. PubMed ID: 24101301
[TBL] [Abstract][Full Text] [Related]
14. Distinct roles of
Myers SJ; Yuan H; Kang JQ; Tan FCK; Traynelis SF; Low CM
F1000Res; 2019; 8():. PubMed ID: 31807283
[TBL] [Abstract][Full Text] [Related]
15. A de novo loss-of-function GRIN2A mutation associated with childhood focal epilepsy and acquired epileptic aphasia.
Gao K; Tankovic A; Zhang Y; Kusumoto H; Zhang J; Chen W; XiangWei W; Shaulsky GH; Hu C; Traynelis SF; Yuan H; Jiang Y
PLoS One; 2017; 12(2):e0170818. PubMed ID: 28182669
[TBL] [Abstract][Full Text] [Related]
16. Memantine and Ketamine Differentially Alter NMDA Receptor Desensitization.
Glasgow NG; Povysheva NV; Azofeifa AM; Johnson JW
J Neurosci; 2017 Oct; 37(40):9686-9704. PubMed ID: 28877967
[TBL] [Abstract][Full Text] [Related]
17.
XiangWei W; Jiang Y; Yuan H
Curr Opin Physiol; 2018 Apr; 2():27-35. PubMed ID: 29756080
[TBL] [Abstract][Full Text] [Related]
18. De novo GRIN2A variants associated with epilepsy and autism and literature review.
Mangano GD; Riva A; Fontana A; Salpietro V; Mangano GR; Nobile G; Orsini A; Iacomino M; Battini R; Astrea G; Striano P; Nardello R
Epilepsy Behav; 2022 Apr; 129():108604. PubMed ID: 35217385
[TBL] [Abstract][Full Text] [Related]
19. Pregnane-based steroids are novel positive NMDA receptor modulators that may compensate for the effect of loss-of-function disease-associated GRIN mutations.
Kysilov B; Hrcka Krausova B; Vyklicky V; Smejkalova T; Korinek M; Horak M; Chodounska H; Kudova E; Cerny J; Vyklicky L
Br J Pharmacol; 2022 Aug; 179(15):3970-3990. PubMed ID: 35318645
[TBL] [Abstract][Full Text] [Related]
20. Binding of ArgTX-636 in the NMDA receptor ion channel.
Poulsen MH; Andersen J; Christensen R; Hansen KB; Traynelis SF; Strømgaard K; Kristensen AS
J Mol Biol; 2015 Jan; 427(1):176-89. PubMed ID: 24862283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
